Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)
Oncology Reports · 2026
DOI: 10.3892/or.2026.9049 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Reports, 2026. Verfasst von Huiyuan Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China.
- National Clinical Research Center for Chinese Medicine, Tianjin 300193, P.R. China.
Zitieren
APA
Ma, H., Li, L., Jiao, C., Cheng, Y., He, J., Jiang, C., Tong, Q., Yi, D., & Zhang, Y. (2026). Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review). Oncology Reports. https://doi.org/10.3892/or.2026.9049
Vancouver
Ma H, Li L, Jiao C, Cheng Y, He J, Jiang C, et al. Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review). Oncology Reports. 2026. doi:10.3892/or.2026.9049
BibTeX
@article{Ma2026,
author = {Ma, Huiyuan and Li, Longhui and Jiao, Conghan and Cheng, Yanyan and He, Jiayu and Jiang, Chen and Tong, Qian and Yi, Dan and Zhang, Ying},
title = {Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)},
journal = {Oncology Reports},
year = {2026},
doi = {10.3892/or.2026.9049}
}
EUVIMED